is semaglutide a sglt2 inhibitor once weekly as add-on to SGLT-2 therapy in type 2 diabetes (SUSTAIN 9): randomised, placebo-controlled trial EMPAGLIFLOZIN — SGLT2 Inhibitor, A

Aside from this lack of difference between the treatment groups, the study had a high dropout rate and, as such, the generalizability of the results of the study should be interpreted with caution

Zareba P, Colaci DS, Afeiche M, et al

External resources for tirzepatide and B12 research Clinical trial data for tirzepatide weight loss efficacy comes primarily from the SURMOUNT trial series published in The New England Journal of Medicine

Placebo: 2.4% weight reduction with 31.5% of participants achieving at least a 5% weight loss

Unlike traditional treatments that target only CSF production, GLP-1 agonists may work through two pathways: Weight loss - a major long-term treatment for IIH Possible CSF pressure effects - GLP-1 receptors on the choroid plexus (where CSF is made) may reduce fluid secretion independent of weight loss The IIH Pressure Trial ( Brain , 2023) found that exenatide lowered intracranial pressure within hours of the first dose

Wang L, Kounatidis I, Ligoxygakis P